Central Valley Advisors LLC Purchases Shares of 48,421 Enovis Co. (NYSE:ENOV)

Central Valley Advisors LLC purchased a new position in Enovis Co. (NYSE:ENOV - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,421 shares of the company's stock, valued at approximately $1,850,000. Central Valley Advisors LLC owned 0.09% of Enovis as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its stake in shares of Enovis by 266.7% in the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after acquiring an additional 536 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Enovis in the fourth quarter worth approximately $29,000. Quadrant Capital Group LLC grew its stake in shares of Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after acquiring an additional 239 shares during the period. Quarry LP grew its stake in shares of Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 749 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Enovis by 144.8% in the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock worth $45,000 after acquiring an additional 692 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Performance

Shares of ENOV traded down $0.43 on Friday, reaching $31.86. The company's stock had a trading volume of 1,365,072 shares, compared to its average volume of 832,306. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market capitalization of $1.82 billion, a P/E ratio of -14.55 and a beta of 1.71. The stock's 50 day simple moving average is $33.24 and its two-hundred day simple moving average is $39.60. Enovis Co. has a 12-month low of $29.13 and a 12-month high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same quarter last year, the firm posted $0.50 earnings per share. The firm's revenue was up 8.2% compared to the same quarter last year. Research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on ENOV shares. Canaccord Genuity Group reduced their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Needham & Company LLC dropped their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, JMP Securities dropped their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $58.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.